At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Pharmacia Corporation
- Class Antipsychotics
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 18 Jul 2001 No-Development-Reported for Psychotic disorders in Sweden (Unknown route)
- 18 Jul 2001 No-Development-Reported for Psychotic disorders in USA (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed